This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published on July 18
Healthcare is rapidly shifting toward more patient-friendly treatments, and these companies are at the forefront. The FDA's recent approval of GSK's pre-filled Shingrix vaccine signals growing demand for simpler delivery solutions.
Major pharma companies are actively seeking innovative delivery systems to differentiate their products in crowded markets. This creates valuable partnership and acquisition opportunities for these specialized firms.
These technologies solve a critical healthcare challenge: patient compliance. By making treatments easier to administer correctly, these companies aren't just improving outcomes—they're creating potentially recurring revenue streams.
The FDA's approval of GSK's pre-filled Shingrix vaccine highlights a significant industry shift toward simplified drug delivery. Companies developing user-friendly delivery systems like pre-filled syringes, wearable pumps, and needle-free options are gaining valuable competitive advantages as pharmaceutical giants seek to differentiate their products.
This group includes companies across the drug delivery value chain, from oral alternatives to injectable medications to sustained-release implants. These innovations aim to reduce healthcare provider burden, minimize administration errors, and improve patient compliance, potentially leading to better clinical outcomes.
These companies were selected based on their position to benefit from the pharmaceutical industry's accelerating adoption of advanced delivery technologies. With proprietary platforms that transform complex treatments into simplified formats, they represent a tactical opportunity in response to recent regulatory validation.
Market capitalisation breakdown for the Next-Generation Drug Delivery Systems basket.
PODD: $23.16B
RANI: $204.83M
AVDL: $1.74B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+4
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+618.60%
On average, analysts expect assets in this group to grow 618.6% over the next year.
11 of 13 assets in this group are rated Buy by professional analysts.
